Save information for later
Sign Up

Learn About Neuroepithelioma

View Main Condition: Brain Tumor

What are the alternative names for Neuroepithelioma?
  • Neuroepithelioma
Who are the top Neuroepithelioma Local Doctors?
Nina Paleologos
Distinguished in Neuroepithelioma
Psychiatry | Neurology
Distinguished in Neuroepithelioma
Psychiatry | Neurology

Advocate Medical Group Neurosurgery

3551 Highland Ave Ste, Ste 200A, 
Downers Grove, IL 
Languages Spoken:
English

Nina Paleologos is a Psychiatrist and a Neurologist in Downers Grove, Illinois. Dr. Paleologos is rated as a Distinguished provider by MediFind in the treatment of Neuroepithelioma. Her top areas of expertise are Oligodendroglioma, Glioma, Glioblastoma, and Astrocytoma.

Glenn J. Lesser
Distinguished in Neuroepithelioma
Oncology | Hematology
Distinguished in Neuroepithelioma
Oncology | Hematology

Wake Forest University Health Sciences

Medical Ctr Blvd, 
Winston Salem, NC 
Languages Spoken:
English
Accepting New Patients

Glenn Lesser is an Oncologist and a Hematologist in Winston Salem, North Carolina. Dr. Lesser is rated as a Distinguished provider by MediFind in the treatment of Neuroepithelioma. His top areas of expertise are Brain Tumor, Glioblastoma, Astrocytoma, Glioma, and Bone Marrow Aspiration. Dr. Lesser is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Neuroepithelioma
Elite in Neuroepithelioma
Sydney, NSW, AU 

Danuta Kalinowski practices in Sydney, Australia. Ms. Kalinowski is rated as an Elite expert by MediFind in the treatment of Neuroepithelioma. Her top areas of expertise are Neuroepithelioma, Hereditary Ataxia, Friedreich Ataxia, and Spinocerebellar Ataxia.

What are the latest Neuroepithelioma Clinical Trials?
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Summary: Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

Summary: This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Gi...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center